0

Close
 
Upcoming Allied Market Research
2023
Diabetic Eye Disease Devices Market

Diabetic Eye Disease Devices Market

by Devices (Surgery, Ophthalmic Diagnostic Monitoring Equipment, Vision Care), by Diseases (Diabetic Retinopathy, Diabetic Macular Edema (DME), Cataract, Glaucoma, Others) and by End-User (Hospitals, Ophthalmic Clinics, OthersOthersOthersOthersOthers): Global Opportunity Analysis and Industry Forecast, 2023-2032

LS : Medical Devices & Supplies
Report Code: A03647
Nov 2023 | Pages: NA
Tables: NA
Charts: NA

  • Formats*:

  • pdf

    Single User License, Five User
    License & Enterprise User License

  • xls

    Data Pack Excel License

  • ppt

    It comes with the additional cost
    of $2500.00 contact sales.
 

COVID-19

Pandemic disrupted the entire world and affected many industries.

Get detailed COVID-19 impact analysis on the Diabetic Eye Disease Devices Market

Request Now !

Diabetic eye disease devices are medical devices used to treat and diagnose renal complications that occur due to diabetes. The most common diabetic eye diseases include diabetic retinopathy, diabetic macular edema, cataract, and glaucoma. These conditions may lead to complete blindness if not treated on time.

The growing prevalence of diabetic eye diseases owning to increasing smoking addiction, eye injury, hormone replacement therapy, and diseases such as diabetes, hypertension, and obesity drive the diabetic eye disease devices market growth. In addition, increasing geriatric population who suffer from diabetic eye diseases increases the market growth.

There is an increasing demand for diabetic eye diseases devices to avoid visual impairment and loss of vision. However, dearth of skilled professionals with expertise in ophthalmic surgery, lack of healthcare infrastructure in developing countries, low awareness of eye surgery, and stringent government regulations associated with the safety & efficacy of medical devices hamper the market growth. Ongoing R&D activities related to diabetic eye disease devices are anticipated to present new opportunities for the market.

The market is segmented on the basis of devices, diseases, end-users, and region. Based on devices, the market is divided into surgery, ophthalmic diagnostic & monitoring equipment, and vision care. Based on diseases the market is categorized into diabetic retinopathy, diabetic macular edema (DME), cataract, glaucoma, and others. Based on end-users the market is segmented into hospitals, ophthalmic clinics, and others. Based on region, the global diabetic eye disease devices market is segmented into North America, Europe, Asia-Pacific, and LAMEA.

Key Benefits:

  • The study provides an in-depth analysis of the global diabetic eye disease devices market, with current trends and future estimations to elucidate investment pockets.
  • Comprehensive analysis of factors that drive and restrict the growth of the market has been provided.
  • The report provides a quantitative analysis to help stakeholders capitalize on prevailing market opportunities in terms of value.
  • Extensive analysis of different segments helps understand various products of the market.
  • Key players have been profiled and their strategies thoroughly analyzed, which predict the competitive outlook of the market.

 Diabetic Eye Disease Devices Market Report Highlights

Aspects Details
By Devices
  • Surgery
    • Cataract Surgery Devices
      • Intra Ocular Lens (IOL)
        • Monofocal
        • Multifocal
        • Toric
        • Accomodating
      • Ophthalmic Viscoelastic Devices
        • Cohesive
        • Dispersive
      • Phacoemulsification Devices
    • Glaucoma Surgery Devices
      • Glaucoma Drainage Devices
      • Glaucoma Lasers
      • Stents and Implants
      • Systems
    • Refractive Surgery Devices
    • Microkeratome
    • Vitreo Retinal Surgery Devices
      • Vitrectomy Machines
      • Photocoagulation Lasers
    • Ophthalmic Lasers
      • Excimer Laser
      • Femtosecond Laser
      • YAG Laser
      • Glaucoma Lasers
      • Photocoagulation Lasers
  • Ophthalmic Diagnostic & Monitoring Equipment
    • Optical Coherence Tomographers (OCT Scanners)
    • Fundus Cameras
      • Non-Mydriatic
      • Mydriatic
      • Others
    • Slit Lamps
    • Visual Field Analyzers/Perimeters
    • Wavefront Aberrometers
    • Ophthalmic Ultrasound Imaging Systems
    • Ophthalmoscopes
    • Tonometers
    • Autorefractors/Phoropters
    • Keratometers
    • Corneal Topographers
    • Retinoscope
    • Pachymeter
    • Specular Microscope
    • Biometers
    • Optotype Projectors
    • Dioptometers
  • Vision Care
    • Contact Lens
    • Spectacles
By Diseases
  • Diabetic Retinopathy
  • Diabetic Macular Edema (DME)
  • Cataract
  • Glaucoma
  • Others
By End-User
  • Hospitals
  • Ophthalmic Clinics
  • OthersOthersOthersOthersOthers
By Region
  • North America  (U.S., Canada, Mexico)
  • Europe  (France, Germany, Italy, Spain, UK, Rest of Europe)
  • Asia-Pacific  (China, Japan, India, South Korea, Australia, Rest of Asia-Pacific)
  • LAMEA  (Brazil, South Africa, Saudi Arabia, Rest of LAMEA)
Key Market Players Nidek Co., Ltd., Novartis AG, Alcon Inc., Valeant Pharmaceuticals International, Inc., STAAR Surgical Company, Actavis plc, Johnson & Johnson, Aaren Scientific Inc., CooperVision AG, Essilor International S.A.
 

  • CHAPTER 1: INTRODUCTION

    • 1.1. Report Description

    • 1.2. Key Market Segments

    • 1.3. Key Benefits

    • 1.4. Research Methodology

      • 1.4.1. Primary Research

      • 1.4.2. Secondary Research

      • 1.4.3. Analyst Tools and Models

  • CHAPTER 2: EXECUTIVE SUMMARY

    • 2.1. CXO Perspective

  • CHAPTER 3: MARKET LANDSCAPE

    • 3.1. Market Definition and Scope

    • 3.2. Key Findings

      • 3.2.1. Top Investment Pockets

      • 3.2.2. Top Winning Strategies

    • 3.3. Porter's Five Forces Analysis

      • 3.3.1. Bargaining Power of Suppliers

      • 3.3.2. Threat of New Entrants

      • 3.3.3. Threat of Substitutes

      • 3.3.4. Competitive Rivalry

      • 3.3.5. Bargaining Power among Buyers

    • 3.5. Market Dynamics

      • 3.5.1. Drivers

      • 3.5.2. Restraints

      • 3.5.3. Opportunities

    • 3.6. COVID-19 Impact Analysis

  • CHAPTER 4: DIABETIC EYE DISEASE DEVICES MARKET, BY DEVICES

    • 4.1. Market Overview

      • 4.1.1 Market Size and Forecast, By Devices

    • 4.2. Surgery

      • 4.2.1. Key Market Trends, Growth Factors and Opportunities

      • 4.2.2. Market Size and Forecast, By Region

      • 4.2.3. Market Share Analysis, By Country

      • 4.2.4. Cataract Surgery Devices

        • 4.2.4.1. Market Size and Forecast

        • 4.2.4.2. Intra Ocular Lens (IOL)

          • 4.2.4.2.1. Market Size and Forecast
          • 4.2.4.2.2. Monofocal
            • 4.2.4.2.2.1. Market Size and Forecast
          • 4.2.4.2.2. Multifocal
            • 4.2.4.2.2.1. Market Size and Forecast
          • 4.2.4.2.2. Toric
            • 4.2.4.2.2.1. Market Size and Forecast
          • 4.2.4.2.2. Accomodating
            • 4.2.4.2.2.1. Market Size and Forecast

        • 4.2.4.2. Ophthalmic Viscoelastic Devices

          • 4.2.4.2.1. Market Size and Forecast
          • 4.2.4.2.2. Cohesive
            • 4.2.4.2.2.1. Market Size and Forecast
          • 4.2.4.2.2. Dispersive
            • 4.2.4.2.2.1. Market Size and Forecast

        • 4.2.4.2. Phacoemulsification Devices

          • 4.2.4.2.1. Market Size and Forecast

      • 4.2.4. Glaucoma Surgery Devices

        • 4.2.4.1. Market Size and Forecast

        • 4.2.4.2. Glaucoma Drainage Devices

          • 4.2.4.2.1. Market Size and Forecast

        • 4.2.4.2. Glaucoma Lasers

          • 4.2.4.2.1. Market Size and Forecast

        • 4.2.4.2. Stents and Implants

          • 4.2.4.2.1. Market Size and Forecast

        • 4.2.4.2. Systems

          • 4.2.4.2.1. Market Size and Forecast

      • 4.2.4. Refractive Surgery Devices

        • 4.2.4.1. Market Size and Forecast

      • 4.2.4. Microkeratome

        • 4.2.4.1. Market Size and Forecast

      • 4.2.4. Vitreo Retinal Surgery Devices

        • 4.2.4.1. Market Size and Forecast

        • 4.2.4.2. Vitrectomy Machines

          • 4.2.4.2.1. Market Size and Forecast

        • 4.2.4.2. Photocoagulation Lasers

          • 4.2.4.2.1. Market Size and Forecast

      • 4.2.4. Ophthalmic Lasers

        • 4.2.4.1. Market Size and Forecast

        • 4.2.4.2. Excimer Laser

          • 4.2.4.2.1. Market Size and Forecast

        • 4.2.4.2. Femtosecond Laser

          • 4.2.4.2.1. Market Size and Forecast

        • 4.2.4.2. YAG Laser

          • 4.2.4.2.1. Market Size and Forecast

        • 4.2.4.2. Glaucoma Lasers

          • 4.2.4.2.1. Market Size and Forecast

        • 4.2.4.2. Photocoagulation Lasers

          • 4.2.4.2.1. Market Size and Forecast

    • 4.3. Ophthalmic Diagnostic Monitoring Equipment

      • 4.3.1. Key Market Trends, Growth Factors and Opportunities

      • 4.3.2. Market Size and Forecast, By Region

      • 4.3.3. Market Share Analysis, By Country

      • 4.3.4. Optical Coherence Tomographers (OCT Scanners)

        • 4.3.4.1. Market Size and Forecast

      • 4.3.4. Fundus Cameras

        • 4.3.4.1. Market Size and Forecast

        • 4.3.4.2. Non-Mydriatic

          • 4.3.4.2.1. Market Size and Forecast

        • 4.3.4.2. Mydriatic

          • 4.3.4.2.1. Market Size and Forecast

        • 4.3.4.2. Others

          • 4.3.4.2.1. Market Size and Forecast

      • 4.3.4. Slit Lamps

        • 4.3.4.1. Market Size and Forecast

      • 4.3.4. Visual Field Analyzers/Perimeters

        • 4.3.4.1. Market Size and Forecast

      • 4.3.4. Wavefront Aberrometers

        • 4.3.4.1. Market Size and Forecast

      • 4.3.4. Ophthalmic Ultrasound Imaging Systems

        • 4.3.4.1. Market Size and Forecast

      • 4.3.4. Ophthalmoscopes

        • 4.3.4.1. Market Size and Forecast

      • 4.3.4. Tonometers

        • 4.3.4.1. Market Size and Forecast

      • 4.3.4. Autorefractors/Phoropters

        • 4.3.4.1. Market Size and Forecast

      • 4.3.4. Keratometers

        • 4.3.4.1. Market Size and Forecast

      • 4.3.4. Corneal Topographers

        • 4.3.4.1. Market Size and Forecast

      • 4.3.4. Retinoscope

        • 4.3.4.1. Market Size and Forecast

      • 4.3.4. Pachymeter

        • 4.3.4.1. Market Size and Forecast

      • 4.3.4. Specular Microscope

        • 4.3.4.1. Market Size and Forecast

      • 4.3.4. Biometers

        • 4.3.4.1. Market Size and Forecast

      • 4.3.4. Optotype Projectors

        • 4.3.4.1. Market Size and Forecast

      • 4.3.4. Dioptometers

        • 4.3.4.1. Market Size and Forecast

    • 4.4. Vision Care

      • 4.4.1. Key Market Trends, Growth Factors and Opportunities

      • 4.4.2. Market Size and Forecast, By Region

      • 4.4.3. Market Share Analysis, By Country

      • 4.4.4. Contact Lens

        • 4.4.4.1. Market Size and Forecast

      • 4.4.4. Spectacles

        • 4.4.4.1. Market Size and Forecast

  • CHAPTER 5: DIABETIC EYE DISEASE DEVICES MARKET, BY DISEASES

    • 5.1. Market Overview

      • 5.1.1 Market Size and Forecast, By Diseases

    • 5.2. Diabetic Retinopathy

      • 5.2.1. Key Market Trends, Growth Factors and Opportunities

      • 5.2.2. Market Size and Forecast, By Region

      • 5.2.3. Market Share Analysis, By Country

    • 5.3. Diabetic Macular Edema (DME)

      • 5.3.1. Key Market Trends, Growth Factors and Opportunities

      • 5.3.2. Market Size and Forecast, By Region

      • 5.3.3. Market Share Analysis, By Country

    • 5.4. Cataract

      • 5.4.1. Key Market Trends, Growth Factors and Opportunities

      • 5.4.2. Market Size and Forecast, By Region

      • 5.4.3. Market Share Analysis, By Country

    • 5.5. Glaucoma

      • 5.5.1. Key Market Trends, Growth Factors and Opportunities

      • 5.5.2. Market Size and Forecast, By Region

      • 5.5.3. Market Share Analysis, By Country

    • 5.6. Others

      • 5.6.1. Key Market Trends, Growth Factors and Opportunities

      • 5.6.2. Market Size and Forecast, By Region

      • 5.6.3. Market Share Analysis, By Country

  • CHAPTER 6: DIABETIC EYE DISEASE DEVICES MARKET, BY END-USER

    • 6.1. Market Overview

      • 6.1.1 Market Size and Forecast, By End-user

    • 6.2. Hospitals

      • 6.2.1. Key Market Trends, Growth Factors and Opportunities

      • 6.2.2. Market Size and Forecast, By Region

      • 6.2.3. Market Share Analysis, By Country

    • 6.3. Ophthalmic Clinics

      • 6.3.1. Key Market Trends, Growth Factors and Opportunities

      • 6.3.2. Market Size and Forecast, By Region

      • 6.3.3. Market Share Analysis, By Country

    • 6.4. OthersOthersOthersOthersOthers

      • 6.4.1. Key Market Trends, Growth Factors and Opportunities

      • 6.4.2. Market Size and Forecast, By Region

      • 6.4.3. Market Share Analysis, By Country

  • CHAPTER 7: DIABETIC EYE DISEASE DEVICES MARKET, BY REGION

    • 7.1. Market Overview

      • 7.1.1 Market Size and Forecast, By Region

    • 7.2. North America

      • 7.2.1. Key Market Trends and Opportunities

      • 7.2.2. Market Size and Forecast, By Devices

      • 7.2.3. Market Size and Forecast, By Diseases

      • 7.2.4. Market Size and Forecast, By End-user

      • 7.2.5. Market Size and Forecast, By Country

      • 7.2.6. U.S. Diabetic Eye Disease Devices Market

        • 7.2.6.1. Market Size and Forecast, By Devices
        • 7.2.6.2. Market Size and Forecast, By Diseases
        • 7.2.6.3. Market Size and Forecast, By End-user

      • 7.2.7. Canada Diabetic Eye Disease Devices Market

        • 7.2.7.1. Market Size and Forecast, By Devices
        • 7.2.7.2. Market Size and Forecast, By Diseases
        • 7.2.7.3. Market Size and Forecast, By End-user

      • 7.2.8. Mexico Diabetic Eye Disease Devices Market

        • 7.2.8.1. Market Size and Forecast, By Devices
        • 7.2.8.2. Market Size and Forecast, By Diseases
        • 7.2.8.3. Market Size and Forecast, By End-user

    • 7.3. Europe

      • 7.3.1. Key Market Trends and Opportunities

      • 7.3.2. Market Size and Forecast, By Devices

      • 7.3.3. Market Size and Forecast, By Diseases

      • 7.3.4. Market Size and Forecast, By End-user

      • 7.3.5. Market Size and Forecast, By Country

      • 7.3.6. France Diabetic Eye Disease Devices Market

        • 7.3.6.1. Market Size and Forecast, By Devices
        • 7.3.6.2. Market Size and Forecast, By Diseases
        • 7.3.6.3. Market Size and Forecast, By End-user

      • 7.3.7. Germany Diabetic Eye Disease Devices Market

        • 7.3.7.1. Market Size and Forecast, By Devices
        • 7.3.7.2. Market Size and Forecast, By Diseases
        • 7.3.7.3. Market Size and Forecast, By End-user

      • 7.3.8. Italy Diabetic Eye Disease Devices Market

        • 7.3.8.1. Market Size and Forecast, By Devices
        • 7.3.8.2. Market Size and Forecast, By Diseases
        • 7.3.8.3. Market Size and Forecast, By End-user

      • 7.3.9. Spain Diabetic Eye Disease Devices Market

        • 7.3.9.1. Market Size and Forecast, By Devices
        • 7.3.9.2. Market Size and Forecast, By Diseases
        • 7.3.9.3. Market Size and Forecast, By End-user

      • 7.3.10. UK Diabetic Eye Disease Devices Market

        • 7.3.10.1. Market Size and Forecast, By Devices
        • 7.3.10.2. Market Size and Forecast, By Diseases
        • 7.3.10.3. Market Size and Forecast, By End-user

      • 7.3.11. Russia Diabetic Eye Disease Devices Market

        • 7.3.11.1. Market Size and Forecast, By Devices
        • 7.3.11.2. Market Size and Forecast, By Diseases
        • 7.3.11.3. Market Size and Forecast, By End-user

      • 7.3.12. Rest Of Europe Diabetic Eye Disease Devices Market

        • 7.3.12.1. Market Size and Forecast, By Devices
        • 7.3.12.2. Market Size and Forecast, By Diseases
        • 7.3.12.3. Market Size and Forecast, By End-user

    • 7.4. Asia-Pacific

      • 7.4.1. Key Market Trends and Opportunities

      • 7.4.2. Market Size and Forecast, By Devices

      • 7.4.3. Market Size and Forecast, By Diseases

      • 7.4.4. Market Size and Forecast, By End-user

      • 7.4.5. Market Size and Forecast, By Country

      • 7.4.6. China Diabetic Eye Disease Devices Market

        • 7.4.6.1. Market Size and Forecast, By Devices
        • 7.4.6.2. Market Size and Forecast, By Diseases
        • 7.4.6.3. Market Size and Forecast, By End-user

      • 7.4.7. Japan Diabetic Eye Disease Devices Market

        • 7.4.7.1. Market Size and Forecast, By Devices
        • 7.4.7.2. Market Size and Forecast, By Diseases
        • 7.4.7.3. Market Size and Forecast, By End-user

      • 7.4.8. India Diabetic Eye Disease Devices Market

        • 7.4.8.1. Market Size and Forecast, By Devices
        • 7.4.8.2. Market Size and Forecast, By Diseases
        • 7.4.8.3. Market Size and Forecast, By End-user

      • 7.4.9. South Korea Diabetic Eye Disease Devices Market

        • 7.4.9.1. Market Size and Forecast, By Devices
        • 7.4.9.2. Market Size and Forecast, By Diseases
        • 7.4.9.3. Market Size and Forecast, By End-user

      • 7.4.10. Australia Diabetic Eye Disease Devices Market

        • 7.4.10.1. Market Size and Forecast, By Devices
        • 7.4.10.2. Market Size and Forecast, By Diseases
        • 7.4.10.3. Market Size and Forecast, By End-user

      • 7.4.11. Thailand Diabetic Eye Disease Devices Market

        • 7.4.11.1. Market Size and Forecast, By Devices
        • 7.4.11.2. Market Size and Forecast, By Diseases
        • 7.4.11.3. Market Size and Forecast, By End-user

      • 7.4.12. Malaysia Diabetic Eye Disease Devices Market

        • 7.4.12.1. Market Size and Forecast, By Devices
        • 7.4.12.2. Market Size and Forecast, By Diseases
        • 7.4.12.3. Market Size and Forecast, By End-user

      • 7.4.13. Indonesia Diabetic Eye Disease Devices Market

        • 7.4.13.1. Market Size and Forecast, By Devices
        • 7.4.13.2. Market Size and Forecast, By Diseases
        • 7.4.13.3. Market Size and Forecast, By End-user

      • 7.4.14. Rest of Asia Pacific Diabetic Eye Disease Devices Market

        • 7.4.14.1. Market Size and Forecast, By Devices
        • 7.4.14.2. Market Size and Forecast, By Diseases
        • 7.4.14.3. Market Size and Forecast, By End-user

    • 7.5. LAMEA

      • 7.5.1. Key Market Trends and Opportunities

      • 7.5.2. Market Size and Forecast, By Devices

      • 7.5.3. Market Size and Forecast, By Diseases

      • 7.5.4. Market Size and Forecast, By End-user

      • 7.5.5. Market Size and Forecast, By Country

      • 7.5.6. Brazil Diabetic Eye Disease Devices Market

        • 7.5.6.1. Market Size and Forecast, By Devices
        • 7.5.6.2. Market Size and Forecast, By Diseases
        • 7.5.6.3. Market Size and Forecast, By End-user

      • 7.5.7. South Africa Diabetic Eye Disease Devices Market

        • 7.5.7.1. Market Size and Forecast, By Devices
        • 7.5.7.2. Market Size and Forecast, By Diseases
        • 7.5.7.3. Market Size and Forecast, By End-user

      • 7.5.8. Saudi Arabia Diabetic Eye Disease Devices Market

        • 7.5.8.1. Market Size and Forecast, By Devices
        • 7.5.8.2. Market Size and Forecast, By Diseases
        • 7.5.8.3. Market Size and Forecast, By End-user

      • 7.5.9. UAE Diabetic Eye Disease Devices Market

        • 7.5.9.1. Market Size and Forecast, By Devices
        • 7.5.9.2. Market Size and Forecast, By Diseases
        • 7.5.9.3. Market Size and Forecast, By End-user

      • 7.5.10. Argentina Diabetic Eye Disease Devices Market

        • 7.5.10.1. Market Size and Forecast, By Devices
        • 7.5.10.2. Market Size and Forecast, By Diseases
        • 7.5.10.3. Market Size and Forecast, By End-user

      • 7.5.11. Rest of LAMEA Diabetic Eye Disease Devices Market

        • 7.5.11.1. Market Size and Forecast, By Devices
        • 7.5.11.2. Market Size and Forecast, By Diseases
        • 7.5.11.3. Market Size and Forecast, By End-user

  • CHAPTER 8: COMPETITIVE LANDSCAPE

    • 8.1. Introduction

    • 8.2. Top Winning Strategies

    • 8.3. Product Mapping Of Top 10 Player

    • 8.4. Competitive Dashboard

    • 8.5. Competitive Heatmap

    • 8.6. Top Player Positioning,2022

  • CHAPTER 9: COMPANY PROFILES

    • 9.1. Novartis AG

      • 9.1.1. Company Overview

      • 9.1.2. Key Executives

      • 9.1.3. Company Snapshot

      • 9.1.4. Operating Business Segments

      • 9.1.5. Product Portfolio

      • 9.1.6. Business Performance

      • 9.1.7. Key Strategic Moves and Developments

    • 9.2. Johnson And Johnson

      • 9.2.1. Company Overview

      • 9.2.2. Key Executives

      • 9.2.3. Company Snapshot

      • 9.2.4. Operating Business Segments

      • 9.2.5. Product Portfolio

      • 9.2.6. Business Performance

      • 9.2.7. Key Strategic Moves and Developments

    • 9.3. Aaren Scientific Inc.

      • 9.3.1. Company Overview

      • 9.3.2. Key Executives

      • 9.3.3. Company Snapshot

      • 9.3.4. Operating Business Segments

      • 9.3.5. Product Portfolio

      • 9.3.6. Business Performance

      • 9.3.7. Key Strategic Moves and Developments

    • 9.4. Valeant Pharmaceuticals International, Inc.

      • 9.4.1. Company Overview

      • 9.4.2. Key Executives

      • 9.4.3. Company Snapshot

      • 9.4.4. Operating Business Segments

      • 9.4.5. Product Portfolio

      • 9.4.6. Business Performance

      • 9.4.7. Key Strategic Moves and Developments

    • 9.5. Essilor International S.A.

      • 9.5.1. Company Overview

      • 9.5.2. Key Executives

      • 9.5.3. Company Snapshot

      • 9.5.4. Operating Business Segments

      • 9.5.5. Product Portfolio

      • 9.5.6. Business Performance

      • 9.5.7. Key Strategic Moves and Developments

    • 9.6. Alcon Inc.

      • 9.6.1. Company Overview

      • 9.6.2. Key Executives

      • 9.6.3. Company Snapshot

      • 9.6.4. Operating Business Segments

      • 9.6.5. Product Portfolio

      • 9.6.6. Business Performance

      • 9.6.7. Key Strategic Moves and Developments

    • 9.7. Nidek Co., Ltd.

      • 9.7.1. Company Overview

      • 9.7.2. Key Executives

      • 9.7.3. Company Snapshot

      • 9.7.4. Operating Business Segments

      • 9.7.5. Product Portfolio

      • 9.7.6. Business Performance

      • 9.7.7. Key Strategic Moves and Developments

    • 9.8. STAAR Surgical Company

      • 9.8.1. Company Overview

      • 9.8.2. Key Executives

      • 9.8.3. Company Snapshot

      • 9.8.4. Operating Business Segments

      • 9.8.5. Product Portfolio

      • 9.8.6. Business Performance

      • 9.8.7. Key Strategic Moves and Developments

    • 9.9. Actavis Plc

      • 9.9.1. Company Overview

      • 9.9.2. Key Executives

      • 9.9.3. Company Snapshot

      • 9.9.4. Operating Business Segments

      • 9.9.5. Product Portfolio

      • 9.9.6. Business Performance

      • 9.9.7. Key Strategic Moves and Developments

    • 9.10. CooperVision AG

      • 9.10.1. Company Overview

      • 9.10.2. Key Executives

      • 9.10.3. Company Snapshot

      • 9.10.4. Operating Business Segments

      • 9.10.5. Product Portfolio

      • 9.10.6. Business Performance

      • 9.10.7. Key Strategic Moves and Developments

  • LIST OF TABLES

  • TABLE 1. GLOBAL DIABETIC EYE DISEASE DEVICES MARKET, BY DEVICES, 2022-2032 ($MILLION)
  • TABLE 2. GLOBAL DIABETIC EYE DISEASE DEVICES MARKET FOR SURGERY, BY REGION, 2022-2032 ($MILLION)
  • TABLE 3. GLOBAL DIABETIC EYE DISEASE DEVICES MARKET FOR OPHTHALMIC DIAGNOSTIC MONITORING EQUIPMENT, BY REGION, 2022-2032 ($MILLION)
  • TABLE 4. GLOBAL DIABETIC EYE DISEASE DEVICES MARKET FOR VISION CARE, BY REGION, 2022-2032 ($MILLION)
  • TABLE 5. GLOBAL DIABETIC EYE DISEASE DEVICES MARKET, BY DISEASES, 2022-2032 ($MILLION)
  • TABLE 6. GLOBAL DIABETIC EYE DISEASE DEVICES MARKET FOR DIABETIC RETINOPATHY, BY REGION, 2022-2032 ($MILLION)
  • TABLE 7. GLOBAL DIABETIC EYE DISEASE DEVICES MARKET FOR DIABETIC MACULAR EDEMA (DME), BY REGION, 2022-2032 ($MILLION)
  • TABLE 8. GLOBAL DIABETIC EYE DISEASE DEVICES MARKET FOR CATARACT, BY REGION, 2022-2032 ($MILLION)
  • TABLE 9. GLOBAL DIABETIC EYE DISEASE DEVICES MARKET FOR GLAUCOMA, BY REGION, 2022-2032 ($MILLION)
  • TABLE 10. GLOBAL DIABETIC EYE DISEASE DEVICES MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 11. GLOBAL DIABETIC EYE DISEASE DEVICES MARKET, BY END-USER, 2022-2032 ($MILLION)
  • TABLE 12. GLOBAL DIABETIC EYE DISEASE DEVICES MARKET FOR HOSPITALS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 13. GLOBAL DIABETIC EYE DISEASE DEVICES MARKET FOR OPHTHALMIC CLINICS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 14. GLOBAL DIABETIC EYE DISEASE DEVICES MARKET FOR OTHERSOTHERSOTHERSOTHERSOTHERS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 15. GLOBAL DIABETIC EYE DISEASE DEVICES MARKET, BY REGION, 2022-2032 ($MILLION)
  • TABLE 16. NORTH AMERICA DIABETIC EYE DISEASE DEVICES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 17. NORTH AMERICA DIABETIC EYE DISEASE DEVICES, BY DEVICES, 2022-2032 ($MILLION)
  • TABLE 18. NORTH AMERICA DIABETIC EYE DISEASE DEVICES, BY DISEASES, 2022-2032 ($MILLION)
  • TABLE 19. NORTH AMERICA DIABETIC EYE DISEASE DEVICES, BY END-USER, 2022-2032 ($MILLION)
  • TABLE 20. U.S. DIABETIC EYE DISEASE DEVICES, BY DEVICES, 2022-2032 ($MILLION)
  • TABLE 21. U.S. DIABETIC EYE DISEASE DEVICES, BY DISEASES, 2022-2032 ($MILLION)
  • TABLE 22. U.S. DIABETIC EYE DISEASE DEVICES, BY END-USER, 2022-2032 ($MILLION)
  • TABLE 23. CANADA DIABETIC EYE DISEASE DEVICES, BY DEVICES, 2022-2032 ($MILLION)
  • TABLE 24. CANADA DIABETIC EYE DISEASE DEVICES, BY DISEASES, 2022-2032 ($MILLION)
  • TABLE 25. CANADA DIABETIC EYE DISEASE DEVICES, BY END-USER, 2022-2032 ($MILLION)
  • TABLE 26. MEXICO DIABETIC EYE DISEASE DEVICES, BY DEVICES, 2022-2032 ($MILLION)
  • TABLE 27. MEXICO DIABETIC EYE DISEASE DEVICES, BY DISEASES, 2022-2032 ($MILLION)
  • TABLE 28. MEXICO DIABETIC EYE DISEASE DEVICES, BY END-USER, 2022-2032 ($MILLION)
  • TABLE 29. EUROPE DIABETIC EYE DISEASE DEVICES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 30. EUROPE DIABETIC EYE DISEASE DEVICES, BY DEVICES, 2022-2032 ($MILLION)
  • TABLE 31. EUROPE DIABETIC EYE DISEASE DEVICES, BY DISEASES, 2022-2032 ($MILLION)
  • TABLE 32. EUROPE DIABETIC EYE DISEASE DEVICES, BY END-USER, 2022-2032 ($MILLION)
  • TABLE 33. FRANCE DIABETIC EYE DISEASE DEVICES, BY DEVICES, 2022-2032 ($MILLION)
  • TABLE 34. FRANCE DIABETIC EYE DISEASE DEVICES, BY DISEASES, 2022-2032 ($MILLION)
  • TABLE 35. FRANCE DIABETIC EYE DISEASE DEVICES, BY END-USER, 2022-2032 ($MILLION)
  • TABLE 36. GERMANY DIABETIC EYE DISEASE DEVICES, BY DEVICES, 2022-2032 ($MILLION)
  • TABLE 37. GERMANY DIABETIC EYE DISEASE DEVICES, BY DISEASES, 2022-2032 ($MILLION)
  • TABLE 38. GERMANY DIABETIC EYE DISEASE DEVICES, BY END-USER, 2022-2032 ($MILLION)
  • TABLE 39. ITALY DIABETIC EYE DISEASE DEVICES, BY DEVICES, 2022-2032 ($MILLION)
  • TABLE 40. ITALY DIABETIC EYE DISEASE DEVICES, BY DISEASES, 2022-2032 ($MILLION)
  • TABLE 41. ITALY DIABETIC EYE DISEASE DEVICES, BY END-USER, 2022-2032 ($MILLION)
  • TABLE 42. SPAIN DIABETIC EYE DISEASE DEVICES, BY DEVICES, 2022-2032 ($MILLION)
  • TABLE 43. SPAIN DIABETIC EYE DISEASE DEVICES, BY DISEASES, 2022-2032 ($MILLION)
  • TABLE 44. SPAIN DIABETIC EYE DISEASE DEVICES, BY END-USER, 2022-2032 ($MILLION)
  • TABLE 45. UK DIABETIC EYE DISEASE DEVICES, BY DEVICES, 2022-2032 ($MILLION)
  • TABLE 46. UK DIABETIC EYE DISEASE DEVICES, BY DISEASES, 2022-2032 ($MILLION)
  • TABLE 47. UK DIABETIC EYE DISEASE DEVICES, BY END-USER, 2022-2032 ($MILLION)
  • TABLE 48. RUSSIA DIABETIC EYE DISEASE DEVICES, BY DEVICES, 2022-2032 ($MILLION)
  • TABLE 49. RUSSIA DIABETIC EYE DISEASE DEVICES, BY DISEASES, 2022-2032 ($MILLION)
  • TABLE 50. RUSSIA DIABETIC EYE DISEASE DEVICES, BY END-USER, 2022-2032 ($MILLION)
  • TABLE 51. REST OF EUROPE DIABETIC EYE DISEASE DEVICES, BY DEVICES, 2022-2032 ($MILLION)
  • TABLE 52. REST OF EUROPE DIABETIC EYE DISEASE DEVICES, BY DISEASES, 2022-2032 ($MILLION)
  • TABLE 53. REST OF EUROPE DIABETIC EYE DISEASE DEVICES, BY END-USER, 2022-2032 ($MILLION)
  • TABLE 54. ASIA-PACIFIC DIABETIC EYE DISEASE DEVICES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 55. ASIA-PACIFIC DIABETIC EYE DISEASE DEVICES, BY DEVICES, 2022-2032 ($MILLION)
  • TABLE 56. ASIA-PACIFIC DIABETIC EYE DISEASE DEVICES, BY DISEASES, 2022-2032 ($MILLION)
  • TABLE 57. ASIA-PACIFIC DIABETIC EYE DISEASE DEVICES, BY END-USER, 2022-2032 ($MILLION)
  • TABLE 58. CHINA DIABETIC EYE DISEASE DEVICES, BY DEVICES, 2022-2032 ($MILLION)
  • TABLE 59. CHINA DIABETIC EYE DISEASE DEVICES, BY DISEASES, 2022-2032 ($MILLION)
  • TABLE 60. CHINA DIABETIC EYE DISEASE DEVICES, BY END-USER, 2022-2032 ($MILLION)
  • TABLE 61. JAPAN DIABETIC EYE DISEASE DEVICES, BY DEVICES, 2022-2032 ($MILLION)
  • TABLE 62. JAPAN DIABETIC EYE DISEASE DEVICES, BY DISEASES, 2022-2032 ($MILLION)
  • TABLE 63. JAPAN DIABETIC EYE DISEASE DEVICES, BY END-USER, 2022-2032 ($MILLION)
  • TABLE 64. INDIA DIABETIC EYE DISEASE DEVICES, BY DEVICES, 2022-2032 ($MILLION)
  • TABLE 65. INDIA DIABETIC EYE DISEASE DEVICES, BY DISEASES, 2022-2032 ($MILLION)
  • TABLE 66. INDIA DIABETIC EYE DISEASE DEVICES, BY END-USER, 2022-2032 ($MILLION)
  • TABLE 67. SOUTH KOREA DIABETIC EYE DISEASE DEVICES, BY DEVICES, 2022-2032 ($MILLION)
  • TABLE 68. SOUTH KOREA DIABETIC EYE DISEASE DEVICES, BY DISEASES, 2022-2032 ($MILLION)
  • TABLE 69. SOUTH KOREA DIABETIC EYE DISEASE DEVICES, BY END-USER, 2022-2032 ($MILLION)
  • TABLE 70. AUSTRALIA DIABETIC EYE DISEASE DEVICES, BY DEVICES, 2022-2032 ($MILLION)
  • TABLE 71. AUSTRALIA DIABETIC EYE DISEASE DEVICES, BY DISEASES, 2022-2032 ($MILLION)
  • TABLE 72. AUSTRALIA DIABETIC EYE DISEASE DEVICES, BY END-USER, 2022-2032 ($MILLION)
  • TABLE 73. THAILAND DIABETIC EYE DISEASE DEVICES, BY DEVICES, 2022-2032 ($MILLION)
  • TABLE 74. THAILAND DIABETIC EYE DISEASE DEVICES, BY DISEASES, 2022-2032 ($MILLION)
  • TABLE 75. THAILAND DIABETIC EYE DISEASE DEVICES, BY END-USER, 2022-2032 ($MILLION)
  • TABLE 76. MALAYSIA DIABETIC EYE DISEASE DEVICES, BY DEVICES, 2022-2032 ($MILLION)
  • TABLE 77. MALAYSIA DIABETIC EYE DISEASE DEVICES, BY DISEASES, 2022-2032 ($MILLION)
  • TABLE 78. MALAYSIA DIABETIC EYE DISEASE DEVICES, BY END-USER, 2022-2032 ($MILLION)
  • TABLE 79. INDONESIA DIABETIC EYE DISEASE DEVICES, BY DEVICES, 2022-2032 ($MILLION)
  • TABLE 80. INDONESIA DIABETIC EYE DISEASE DEVICES, BY DISEASES, 2022-2032 ($MILLION)
  • TABLE 81. INDONESIA DIABETIC EYE DISEASE DEVICES, BY END-USER, 2022-2032 ($MILLION)
  • TABLE 82. REST OF ASIA PACIFIC DIABETIC EYE DISEASE DEVICES, BY DEVICES, 2022-2032 ($MILLION)
  • TABLE 83. REST OF ASIA PACIFIC DIABETIC EYE DISEASE DEVICES, BY DISEASES, 2022-2032 ($MILLION)
  • TABLE 84. REST OF ASIA PACIFIC DIABETIC EYE DISEASE DEVICES, BY END-USER, 2022-2032 ($MILLION)
  • TABLE 85. LAMEA DIABETIC EYE DISEASE DEVICES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 86. LAMEA DIABETIC EYE DISEASE DEVICES, BY DEVICES, 2022-2032 ($MILLION)
  • TABLE 87. LAMEA DIABETIC EYE DISEASE DEVICES, BY DISEASES, 2022-2032 ($MILLION)
  • TABLE 88. LAMEA DIABETIC EYE DISEASE DEVICES, BY END-USER, 2022-2032 ($MILLION)
  • TABLE 89. BRAZIL DIABETIC EYE DISEASE DEVICES, BY DEVICES, 2022-2032 ($MILLION)
  • TABLE 90. BRAZIL DIABETIC EYE DISEASE DEVICES, BY DISEASES, 2022-2032 ($MILLION)
  • TABLE 91. BRAZIL DIABETIC EYE DISEASE DEVICES, BY END-USER, 2022-2032 ($MILLION)
  • TABLE 92. SOUTH AFRICA DIABETIC EYE DISEASE DEVICES, BY DEVICES, 2022-2032 ($MILLION)
  • TABLE 93. SOUTH AFRICA DIABETIC EYE DISEASE DEVICES, BY DISEASES, 2022-2032 ($MILLION)
  • TABLE 94. SOUTH AFRICA DIABETIC EYE DISEASE DEVICES, BY END-USER, 2022-2032 ($MILLION)
  • TABLE 95. SAUDI ARABIA DIABETIC EYE DISEASE DEVICES, BY DEVICES, 2022-2032 ($MILLION)
  • TABLE 96. SAUDI ARABIA DIABETIC EYE DISEASE DEVICES, BY DISEASES, 2022-2032 ($MILLION)
  • TABLE 97. SAUDI ARABIA DIABETIC EYE DISEASE DEVICES, BY END-USER, 2022-2032 ($MILLION)
  • TABLE 98. UAE DIABETIC EYE DISEASE DEVICES, BY DEVICES, 2022-2032 ($MILLION)
  • TABLE 99. UAE DIABETIC EYE DISEASE DEVICES, BY DISEASES, 2022-2032 ($MILLION)
  • TABLE 100. UAE DIABETIC EYE DISEASE DEVICES, BY END-USER, 2022-2032 ($MILLION)
  • TABLE 101. ARGENTINA DIABETIC EYE DISEASE DEVICES, BY DEVICES, 2022-2032 ($MILLION)
  • TABLE 102. ARGENTINA DIABETIC EYE DISEASE DEVICES, BY DISEASES, 2022-2032 ($MILLION)
  • TABLE 103. ARGENTINA DIABETIC EYE DISEASE DEVICES, BY END-USER, 2022-2032 ($MILLION)
  • TABLE 104. REST OF LAMEA DIABETIC EYE DISEASE DEVICES, BY DEVICES, 2022-2032 ($MILLION)
  • TABLE 105. REST OF LAMEA DIABETIC EYE DISEASE DEVICES, BY DISEASES, 2022-2032 ($MILLION)
  • TABLE 106. REST OF LAMEA DIABETIC EYE DISEASE DEVICES, BY END-USER, 2022-2032 ($MILLION)
  • TABLE 107. NOVARTIS AG: KEY EXECUTIVES
  • TABLE 108. NOVARTIS AG: COMPANY SNAPSHOT
  • TABLE 109. NOVARTIS AG: OPERATING SEGMENTS
  • TABLE 110. NOVARTIS AG: PRODUCT PORTFOLIO
  • TABLE 111. NOVARTIS AG: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 112. JOHNSON AND JOHNSON: KEY EXECUTIVES
  • TABLE 113. JOHNSON AND JOHNSON: COMPANY SNAPSHOT
  • TABLE 114. JOHNSON AND JOHNSON: OPERATING SEGMENTS
  • TABLE 115. JOHNSON AND JOHNSON: PRODUCT PORTFOLIO
  • TABLE 116. JOHNSON AND JOHNSON: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 117. AAREN SCIENTIFIC INC.: KEY EXECUTIVES
  • TABLE 118. AAREN SCIENTIFIC INC.: COMPANY SNAPSHOT
  • TABLE 119. AAREN SCIENTIFIC INC.: OPERATING SEGMENTS
  • TABLE 120. AAREN SCIENTIFIC INC.: PRODUCT PORTFOLIO
  • TABLE 121. AAREN SCIENTIFIC INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 122. VALEANT PHARMACEUTICALS INTERNATIONAL, INC.: KEY EXECUTIVES
  • TABLE 123. VALEANT PHARMACEUTICALS INTERNATIONAL, INC.: COMPANY SNAPSHOT
  • TABLE 124. VALEANT PHARMACEUTICALS INTERNATIONAL, INC.: OPERATING SEGMENTS
  • TABLE 125. VALEANT PHARMACEUTICALS INTERNATIONAL, INC.: PRODUCT PORTFOLIO
  • TABLE 126. VALEANT PHARMACEUTICALS INTERNATIONAL, INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 127. ESSILOR INTERNATIONAL S.A.: KEY EXECUTIVES
  • TABLE 128. ESSILOR INTERNATIONAL S.A.: COMPANY SNAPSHOT
  • TABLE 129. ESSILOR INTERNATIONAL S.A.: OPERATING SEGMENTS
  • TABLE 130. ESSILOR INTERNATIONAL S.A.: PRODUCT PORTFOLIO
  • TABLE 131. ESSILOR INTERNATIONAL S.A.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 132. ALCON INC.: KEY EXECUTIVES
  • TABLE 133. ALCON INC.: COMPANY SNAPSHOT
  • TABLE 134. ALCON INC.: OPERATING SEGMENTS
  • TABLE 135. ALCON INC.: PRODUCT PORTFOLIO
  • TABLE 136. ALCON INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 137. NIDEK CO., LTD.: KEY EXECUTIVES
  • TABLE 138. NIDEK CO., LTD.: COMPANY SNAPSHOT
  • TABLE 139. NIDEK CO., LTD.: OPERATING SEGMENTS
  • TABLE 140. NIDEK CO., LTD.: PRODUCT PORTFOLIO
  • TABLE 141. NIDEK CO., LTD.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 142. STAAR SURGICAL COMPANY: KEY EXECUTIVES
  • TABLE 143. STAAR SURGICAL COMPANY: COMPANY SNAPSHOT
  • TABLE 144. STAAR SURGICAL COMPANY: OPERATING SEGMENTS
  • TABLE 145. STAAR SURGICAL COMPANY: PRODUCT PORTFOLIO
  • TABLE 146. STAAR SURGICAL COMPANY: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 147. ACTAVIS PLC: KEY EXECUTIVES
  • TABLE 148. ACTAVIS PLC: COMPANY SNAPSHOT
  • TABLE 149. ACTAVIS PLC: OPERATING SEGMENTS
  • TABLE 150. ACTAVIS PLC: PRODUCT PORTFOLIO
  • TABLE 151. ACTAVIS PLC: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 152. COOPERVISION AG: KEY EXECUTIVES
  • TABLE 153. COOPERVISION AG: COMPANY SNAPSHOT
  • TABLE 154. COOPERVISION AG: OPERATING SEGMENTS
  • TABLE 155. COOPERVISION AG: PRODUCT PORTFOLIO
  • TABLE 156. COOPERVISION AG: KEY STRATEGIC MOVES AND DEVELOPMENTS

  • LIST OF FIGURES

  • FIGURE 1. GLOBAL DIABETIC EYE DISEASE DEVICES MARKET SEGMENTATION
  • FIGURE 2. GLOBAL DIABETIC EYE DISEASE DEVICES MARKET
  • FIGURE 3. SEGMENTATION DIABETIC EYE DISEASE DEVICES MARKET
  • FIGURE 4. TOP INVESTMENT POCKET IN DIABETIC EYE DISEASE DEVICES MARKET
  • FIGURE 5. MODERATE BARGAINING POWER OF BUYERS
  • FIGURE 6. MODERATE BARGAINING POWER OF SUPPLIERS
  • FIGURE 7. MODERATE THREAT OF NEW ENTRANTS
  • FIGURE 8. LOW THREAT OF SUBSTITUTION
  • FIGURE 9. HIGH COMPETITIVE RIVALRY
  • FIGURE 10. OPPORTUNITIES, RESTRAINTS AND DRIVERS: GLOBALDIABETIC EYE DISEASE DEVICES MARKET
  • FIGURE 11. DIABETIC EYE DISEASE DEVICES MARKET SEGMENTATION, BY BY DEVICES
  • FIGURE 12. DIABETIC EYE DISEASE DEVICES MARKET FOR SURGERY, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 13. DIABETIC EYE DISEASE DEVICES MARKET FOR OPHTHALMIC DIAGNOSTIC MONITORING EQUIPMENT, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 14. DIABETIC EYE DISEASE DEVICES MARKET FOR VISION CARE, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 15. DIABETIC EYE DISEASE DEVICES MARKET SEGMENTATION, BY BY DISEASES
  • FIGURE 16. DIABETIC EYE DISEASE DEVICES MARKET FOR DIABETIC RETINOPATHY, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 17. DIABETIC EYE DISEASE DEVICES MARKET FOR DIABETIC MACULAR EDEMA (DME), BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 18. DIABETIC EYE DISEASE DEVICES MARKET FOR CATARACT, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 19. DIABETIC EYE DISEASE DEVICES MARKET FOR GLAUCOMA, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 20. DIABETIC EYE DISEASE DEVICES MARKET FOR OTHERS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 21. DIABETIC EYE DISEASE DEVICES MARKET SEGMENTATION, BY BY END-USER
  • FIGURE 22. DIABETIC EYE DISEASE DEVICES MARKET FOR HOSPITALS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 23. DIABETIC EYE DISEASE DEVICES MARKET FOR OPHTHALMIC CLINICS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 24. DIABETIC EYE DISEASE DEVICES MARKET FOR OTHERSOTHERSOTHERSOTHERSOTHERS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 25. TOP WINNING STRATEGIES, BY YEAR, 2020-2022*
  • FIGURE 26. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2020-2022*
  • FIGURE 27. TOP WINNING STRATEGIES, BY COMPANY, 2020-2022*
  • FIGURE 28. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 29. COMPETITIVE DASHBOARD
  • FIGURE 30. COMPETITIVE HEATMAP: DIABETIC EYE DISEASE DEVICES MARKET
  • FIGURE 31. Top player positioning, 2022
  • FIGURE 32. NOVARTIS AG: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 33. NOVARTIS AG: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 34. NOVARTIS AG: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 35. JOHNSON AND JOHNSON: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 36. JOHNSON AND JOHNSON: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 37. JOHNSON AND JOHNSON: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 38. AAREN SCIENTIFIC INC.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 39. AAREN SCIENTIFIC INC.: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 40. AAREN SCIENTIFIC INC.: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 41. VALEANT PHARMACEUTICALS INTERNATIONAL, INC.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 42. VALEANT PHARMACEUTICALS INTERNATIONAL, INC.: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 43. VALEANT PHARMACEUTICALS INTERNATIONAL, INC.: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 44. ESSILOR INTERNATIONAL S.A.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 45. ESSILOR INTERNATIONAL S.A.: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 46. ESSILOR INTERNATIONAL S.A.: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 47. ALCON INC.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 48. ALCON INC.: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 49. ALCON INC.: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 50. NIDEK CO., LTD.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 51. NIDEK CO., LTD.: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 52. NIDEK CO., LTD.: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 53. STAAR SURGICAL COMPANY: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 54. STAAR SURGICAL COMPANY: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 55. STAAR SURGICAL COMPANY: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 56. ACTAVIS PLC: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 57. ACTAVIS PLC: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 58. ACTAVIS PLC: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 59. COOPERVISION AG: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 60. COOPERVISION AG: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 61. COOPERVISION AG: REVENUE SHARE, BY REGION, 2032 (%)

 
 
With collective industry experience of about 200 years of its analysts and experts, Allied Market Research (AMR) encompasses most infallible research methodology for its market intelligence and industry analysis. We do not only engrave the deepest levels of markets but also sneak through its slimmest details for the purpose of our market estimates and forecasts. Our approach helps in building greater market consensus view for size, shape and industry trends within each industry segment. We carefully factor in industry trends and real developments for identifying key growth factors and future course of the market. Our research proceeds are the resultant of high quality data, expert views and analysis and high value independent opinions. Our research process is designed to deliver balanced view of the global markets and allow stakeholders to make informed decisions.

We offer our clients exhaustive research and analysis based on wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics and regional intelligence. Our in-house industry experts play instrumental role in designing analytic tools and models, tailored to the requirements of particular industry segment. These analytical tools and models sanitize the data & statistics and enhance the accuracy of our recommendations and advice. With AMR’s calibrated research process and 360` degree data-evaluation methodology, our clients are assured of receiving:

  • Consistent, valuable, robust and actionable data & analysis that can easily be referenced for strategic business planning
  • Technologically sophisticated and reliable insights through well audited and veracious research methodology
  • Sovereign research proceeds that present a tangible depiction of marketplace


With a strong methodology we are, therefore, confident that our research and analysis are most reliable and guarantees sound business planning.

Secondary research
We refer a broad array of industry sources for our secondary, which typically include; however, not limited to: Company SEC filings, annual reports, company websites, broker & financial reports and investor presentations for competitive scenario and shape of the industry

  • Patent and regulatory databases for understanding of technical & legal developments
  • Scientific and technical writings for product information and related preemptions
  • Regional government and statistical databases for macro analysis
  • Authentic new articles, web-casts and other related releases for market evaluation
  • Internal and external proprietary databases, key market indicators and relevant press releases for market estimates and forecast


Primary research
Our primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks and face-to-face interactions. We are also in professional corporate relations with various companies that allow us greater flexibility for reaching out industry participants and commentators for interviews and discussions, fulfilling following functions:

  • Validates and improves the data quality and strengthens research proceeds
  • Further develops analyst team’s market understanding and expertise
  • Supplies authentic information about market size, share, growth and forecasts


Our primary research interview and discussion panels are typically composed of most experienced industry members. These participants include; however, not limited to:

  • Chief executives and VPs of leading corporations specific to industry
  • Product and sales managers or country heads; channel partners and top level distributors; banking, investments and valuation experts Key opinion leaders (KOLs)


Analyst tools and models
AMR has developed set of analyst tools and data models to supplement and expedite the analysis process. Corresponding to markets, where there is significant lack of information and estimates, AMR’s team of experts and analyst develop specific analyst tools and industry models to translate qualitative and quantitative industry indicators into exact industry estimates. These models also allow analysts to examine the prospects and opportunities prevailing in the market to accurately forecast the course of the market.

PURCHASE OPTIONS

Call or Email us

U.S.-Canada Toll-free: +1-800-792-5285
Int'l : +1-503-894-6022
Europe : +44-845-528-1300
Email : help@alliedmarketresearch.com

Looking for Customization?

 Customization Request

Have a Question?

 Speak with Analyst

Any Confusion?

 Inquire Before Buying

Have a glance of the Report

  Enquiry Now

Purchase Full Report of
Diabetic Eye Disease Devices Market

Start reading.
This Report and over 67,404+ more Reports, Available with Avenue Library. T&C*.

  • Online Only
  • $3,690
  • Online cloud access only
  • Restricted print, copy, paste & download
  • Read only
  • Free industry update
    (Within 180 days)
  • Free report update in next update cycle
  • Data Pack
  • $3,840
  • Restricted to one authorized user
  • One print only
  • Available in
    Excel
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
  • Single User
  • $5,820
  • Restricted to one authorized user
  • One print only
  • Available in
    PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
  • Five Users
  • $6,540
  • Limited to five authorized users
  • Print upto five copies
  • Available in
    PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle

  • Enterprise
    License/PDF

  • $9,870
  • Unlimited
    within
    company/enterprise
  • Available in Excel & PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle

  • Library
    Membership

  • $999 $ 1,175
    Per User/ Per month/ Billed annually
  • Published Content
    E-access
  • Company Profiles
    E-access
  • Newly Added Content Access
  • 10 PDF
    Downloads
  • 5 Excel Data
    Pack Downloads
  • 250 Company Profiles PDF Downloads
  • Buy Now

*Taxes/Fees, if applicable will be added during checkout. All prices in USD

RELATED REPORTS
 

Why Allied Market Research?

 

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers

Get fresh content delivered

Get insights on topics that are crucial for your business. Stay abreast of your interest areas.

Get Industry Data Alerts

Why Allied Market Research?

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers